Vertex Pharmaceuticals shares slipped 2.36% in the most recent trading session, underperforming the broader market advance. This marks the third decline in the past five sessions and follows a period of sideways trading between $430 and $460. Trading volume rose 15% above the 30-day average, suggesting heightened investor activity around the pullback.

In its latest quarterly report, Vertex delivered cystic fibrosis revenues of just over $3 billion, up 8% year-over-year. Management reiterated its full-year outlook of up to $12 billion in total product sales, underpinned by sustained demand for its triple-combination CF therapies. Gross margin remains robust at 86%, supporting continued investment in R&D without sacrificing profitability.

Beyond cystic fibrosis, Vertex is broadening its portfolio with Casgevy for blood disorders, which crossed $100 million in annual sales during its first full year on the market. The company also expects prescriptions for its pain medicine, Journavx, to triple in the coming 12 months after doctors wrote roughly 500,000 scripts last year. These non-CF assets now represent nearly 5% of total revenues and are slated to contribute more meaningfully as they move through late-stage clinical trials.